Research and Markets (http://www.researchandmarkets.com/research/w7g2gd/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and helps to create effective counter-strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Relapsed Chronic Lymphocytic Leukemia (CLL) Overview
- Therapeutics Development
- Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview
- Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
- 4SC AG
- AbbVie Inc.
- Astellas Pharma Inc.
- Astex Pharmaceuticals, Inc.
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Celgene Corporation
- Cyclacel Pharmaceuticals, Inc.
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Hutchison MediPharma Limited
- ImmunoGen, Inc.
- Immunomedics, Inc.
- Incyte Corporation
- Infinity Pharmaceuticals, Inc.
- Innate Pharma S.A.
- Juno Therapeutics Inc.
- Karyopharm Therapeutics, Inc.
- Les Laboratoires Servier SAS
- LFB S.A.
- Lymphocyte Activation Technologies, S.A.
- MedImmune, LLC
- Millennium Pharmaceuticals, Inc.
- MorphoSys AG
- Novartis AG
- Ono Pharmaceutical Co., Ltd.
- Portola Pharmaceuticals, Inc.
- Sanofi
- TG Therapeutics, Inc.
- Threshold Pharmaceuticals, Inc.
- Tragara Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/w7g2gd/relapsed_chronic.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160205005788/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology,
Leukemia
